352458-37-8

Basic information

• Product Name: ABT-492 MegluMine
• Synonyms: ABT 492 MegluMine;ABT492 MegluMine;ABT-492 MegluMine;Delafloxacin (MegluMine);ABT-492MegluMine/ABT492MegluMine;(2R,3R,4R,5S)-6-(MethylaMino)hexane-1,2,3,4,5-pentaol 1-(6-aMino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate;(2R,3R,4R,5S)-2,3,4,5-tetrahydroxy-6-(MethylaMino)hexyl 1-(6-aMino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate;(2R,3R,4R,5S)-2,3,4,5-Tetrahydroxy-6-(methylamino)hexyl 1-(6-amino-3,5-difluoropyridin-2-yl)-8
• CAS NO: 352458-37-8
• Molecular Formula: C₇H₁₇NO₅*C₁₈H₁₂ClF₃N₄O₄
• Molecular Weight: 635.97
• Product Categories: API
• Mol File: 352458-37-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: ABT-492 MegluMine(CAS DataBase Reference)
• NIST Chemistry Reference: ABT-492 MegluMine(352458-37-8)
• EPA Substance Registry System: ABT-492 MegluMine(352458-37-8)

Safety Data

• Hazardous Substances Data: 352458-37-8(Hazardous Substances Data)

Usage

Physical Form

Solid

Description

Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials.

Uses

Delafloxacin is a broad-spectrum anionic fluoroquinolone and its distinct chemical structure increases its potency in acidic environments. It is known to inhibit DNA replication and repair by targeting DNA gyrase and topoisomerase IV. Delafloxacin is administered via both oral and parenteral routes. It has potent activity against methicillin-resistant Staphylococcus aureus and Streptococci, and is also effective against Enterobacteriaceae and Pseudomonas aeruginosa.

Biological Activity

Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine is a broad spectrum fluoroquinolone antibiotic. Delafloxacin has a wide range of activity against drug-resistant Staphylococcus aureus, Streptococcus pneumoniae and Klebsiella pneumoniae.

Upstream product

• 6284-40-8 1-deoxy-1-(methylamino)-D-glucitol 
• 189279-58-1 delafloxacin 
• 189279-51-4 1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-1,4-dihydro-7-fluoro-4-oxo-3-quinolinecarboxylic acid ethyl ester 
• 442526-91-2 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-isobutyryloxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 906088-96-8 C₁₇H₁₁F₄N₃O₃ 
• 875712-88-2 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-isobutyryloxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 

Relevant articles and documents

Refining method of ciprofloxacin and meglumine hydrochloride thereof

The invention provides a preparation process of ciprofloxacin and meglumine thereof. The intermediate product DLSX07 is stirred at Branson ° C. 20% minutes and then sonicated until the solution is cloudy, stirred at room temperature for a period 30s, stirred at room temperature 3h, cooled and slowly added to distilled water, and filtered through suction filtration and filter cake vacuum drying to obtain a pale yellow powder, and 4% the KOH mixture is subjected to ultrasonic treatment 40 - 50 °C. 1. The process is performed by stirring 5h. NCS .t. The solution is cloudy. LC-MS / MS detection powder is deltafloxacin, distilled water is added, and meglumine is mixed to obtain a deltafloxacin meglumine salt. By optimizing the preparation process, the use of the organic solvent is reduced, the reaction time is shortened, and the ice bath and the addition of the interface carrier material contribute to the improvement of the yield.

Preparation method of Delafloxacin and intermediates thereof

The invention relates to a preparation method of Delafloxacin and intermediates thereof. The method comprises the following steps: firstly, taking 3-chloro-2,4,5-fluorobenzoic acid (compound 1) as a raw material and reacting the raw material with thionyl

Preparation method of high-purity delafloxacin meglumine salt

The invention relates to a method for refining a delafloxacin intermediate compound shown in a formula I. The method comprises the following steps: dissolving the compound in the formula I in a good solvent, mixing the compound with a poor solvent, heatin